80 results about "Pulmonary inflammation" patented technology

The present application discloses methods for myocardial imaging in human patients having a history of pulmonary disease such as asthma, bronchospasm, chronic obstructive pulmonary disease, pulmonary fibrosis, pulmonary inflammation, or pulmonary hypertension, comprising administrating doses of one or more A_2A adenosine receptor agonists to a mammal undergoing myocardial imaging and detecting and/or diagnosing myocardial dysfunction.

Disclosed are novel compounds that are A_2B adenosine receptor antagonists having the following structure:

wherein R¹ and R² are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, and R⁴ is an optionally substituted heteroaryl moiety. The compounds of the invention are useful for treating various disease states, including asthma, chronic obstructive pulmonary disorder, pulmonary inflammation, emphysema, diabetic disorders, inflammatory gastrointestinal tract disorders, immunological/inflammatory disorders, cardiovascular diseases, neurological disorders, and diseases related to angiogenesis.

The invention features methods of treating a subject having a lung disorder such as lung inflammation and injury, by administering antithrombin III through pulmonary delivery.

This invention provides compounds of the formula:

wherein R¹ and R² together with the phenyl to which they are bound may form a bicyclic, fused heterocyclic ring and all other variables are as defined herein, their use in pulmonary inflammation or bronchoconstriction therapy and compositions comprising and processes for preparing the same are provided.

The present invention encompasses compositions and methods directed to preventing, inhibiting, or treating inflammation, alveolar remodeling, or cell death in lung which results from elevation of IL-18, IFN-γ, or PKR where the methods of the present invention comprise administering an IL-18 inhibitor, an IL-18Rα inhibitor, and IFNγ inhibitor, a PKR inhibitor, and any combination thereof to an individual experiencing inflammation, alveolar remodeling, or cell death in lung. The present invention further encompasses a method of alleviating exacerbations of COPD frequently caused by viral infection by administering inflammation, alveolar remodeling, or cell death in lung to a patient with COPD at risk of developing a viral infection or who has acquired a viral infection.

Provided are compounds of Formula I:

R¹ and R² together with the phenyl to which they are bound may form a bicyclic, fused heterocyclic ring, and all other variables are as defined herein, as well as their use in treating pulmonary inflammation or bronchoconstriction and compositions comprising and processes for preparing the same.

The invention provides compositions and methods for treating pulmonary conditions and for reducing the negative effects of pulmonary inflammation. Such compositions and methods employ protease inhibitors and a lung surfactant mixture. The compositions and methods can also include lipase inhibitors (e.g. a phospholipase inhibitors) and anti-oxidants.

The invention relates to a Chinese medicinal composition and application of a drug containing the same to treating avian influenza. Various preparations containing the Chinese medicinal composition can effectively prevent and control the avian influenza. An anti-avian influenza animal screening test is performed to screen protective action of the Chinese medicinal composition on mice infected with H5N1 and H9N2 strains respectively, and the Chinese medicinal composition can obviously inhibit pulmonary inflammation of the mice caused by avian influenza viruses, reduce death rate of the mice infected with the avian influenza viruses and prolong survival time of the mice, and has obvious avian influenza resistance. The medicinal composition is made from the following herbs: dandelion, Chinese violet, baikal skullcap root, holly root, red peony root, radix trichosanthis, figwort, angelica, ledebouriella root, bupleurum root, Chinese honeylocust spine, artificial cow-bezoar, dahurian angelica, arisaema with bile, giant knotweed, ptunella spike and isatis root. The herbs are combined to allow various herbs to produce synergetic efficacy, and the Chinese medicinal composition has efficacy of clearing away heat and toxic material, activating blood circulation and cooling blood, relieving inflammation and pain.

The invention discloses an antagonistic drug against replication of a porcine reproductive and respiratory syndrome virus (PRRSV) and application of the antagonistic drug. A virus infection test is adopted, and Xanthohumol (Xn), the antagonistic drug of the PRRSV, is discovered for the first time from a natural medicine library with 386 plant sources. The drug can effectively inhibit PRRSV replication in both Marc-145 and PAM cells, five xanthohumol derivatives with different molecular structures are artificially synthesized, and the viral infection test further finds that the inhibition effect to virus replication by drug derivative Xn-4 is highest in vitro; and test results of artificial infection and drug therapy in piglets show that the Xn-4 can effectively inhibit PRRSV viremia, relieves clinical symptoms of infected pigs, and significantly reduces pulmonary inflammation and pathological damage. Combined with the results, it is proved that the antagonistic drug has important preventive and therapeutic effects to a porcine reproductive and respiratory syndrome, and has important application prospects.

Active agents and compositions that promote barrier function or that inhibit permeability of the vascular endothelium associated with pulmonary inflammation are described.

The present invention includes methods for treating allergic conditions involving the airway by administering histamine receptor antagonists.

The invention discloses application of cobra venom in preparation of a medicament for treating lung inflammatory disease and pulmonary fibrosis. Animal experiment proves that Chinese cobra venom can alleviate acute endotoxin poisoning symptom within a range of 10-3000mug/kg, particularly has obvious therapeutic action on lung inflammatory disease caused by endotoxin, and can be used for alleviating inflammatory cell infiltration, alveolar septum thickening, and focal atelectasis and emphysema. Repeated small dose of endotoxin can result in pulmonary fibrosis, the cobra venom can significantly alleviate pulmonary fibrosis symptom and reduce alveoli damage and collagen hyperplasia. Naturally-modified Chinese cobra venom and physically-modified Chinese cobra venom have similar actions, but the physically-modified Chinese cobra venom has better action. Used for treating lung inflammatory disease, the Chinese cobra venom has the advantages of low dose, safety, capability of being orally administrated, injected, and administered through oral mucous membrane and skin and the like.

A mutual prodrug of an AISTM and a β-agonist in formulation for delivery by aerosolization to inhibit pulmonary inflammation and bronchoconstriction is described. The mutual prodrug is preferably formulated in a small volume solution (10-500 μL) dissolved in a quarter normal saline having pH between about 5.0 and 7.0 for the treatment of respiratory tract inflammation and bronchoconstriction by an aerosol having mass median average diameter predominantly between about 1 to 5μ, produced by nebulization or by dry powder inhaler.

The invention relates to the application of naringenin in the preparation of medicine for curing pneumonia. The effect in staphylococcus aureus infection curing is proved through a rabbit erythrocyte hemolytic test, a pulmonary epithelial cell (A549) damage protection test and a mouse staphylococcus aureus pulmonary inflammation model. Compared with antibiotic therapy, naringenin therapy has the characteristics of no drug tolerance and high cure rate.

The invention discloses a F-18 tagged P2X7 receptor imaging agent which is a compound 18F-{(2-chloro-3-trifluorophenyl)(1-(pyrimidin-2-yl)-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)methanone shown as formula I. The P2X7 receptor imaging agent is suitable for identifying and diagnosing pulmonary inflammation and tumors.

The invention discloses an application of a traditional Chinese medicine composition in preparation of drugs for adjuvant therapy of novel coronavirus pneumonia. The traditional Chinese medicine composition comprises the raw materials: radix puerariae, radix scutellariae, rhizoma coptidis and radix glycyrrhizae preparata. Pneumonia patients infected by novel coronavirus mainly show fever, cough, dyspnea and the like, and part of the pneumonia patients can also show digestive system symptoms such as poor appetite, nausea, emesis, diarrhea and the like. Clinical experiments find that the traditional Chinese medicine composition has a good adjuvant therapy effect on novel coronavirus pneumonia in combination with conventional therapy, can quickly stabilize the condition of an illness, and particularly has a more obvious effect on improving cough, chest distress, nausea, vomiting, loose stool and the like. The average antipyretic time is 3 days, the average nucleic acid negative conversiontime is 8 days, and the clinical cure rate is 100%. The traditional Chinese medicine composition disclosed by the invention can block the conversion of mild and common pneumonia patients into severeand critical pneumonia patients; clinical symptoms of patients can be actively improved; lung inflammatory absorption can be well promoted; safe and reliable use is achieved.

Abstract of the Disclosure

The invention provides a method of, and a kit for, assessing a pulmonary abnormality in a human by providing a standard that relates a degree of pulmonary abnormality with a level of a prostaglandin E₂ metabolite, determining the level of the prostaglandin E₂ metabolite in a human, and comparing the level determined in the human to the standard whereby the pulmonary abnormality in the human is assessed.

The invention relates to a new use of a drug, and specifically relates to an effect of atorvastatin on preparation of a drug for treating pulmonary hypertension. The invention discovers for the first time that atorvastatin is capable of alleviating MCT (Monocrotaline)-induced pulmonary inflammation, and inhibiting pulmonary vascular remodeling, pulmonary artery rising and right ventricular hypertrophy without affecting the body circulating pressure; NF-kB is possible to play an important role in the MCT-induced pulmonary hypertension; the atorvastatin is capable of inhibiting the inflammatory reaction by reducing the expression of the MCT-induced pulmonary hypertension lung tissue NF-kB, and is capable of reducing pulmonary vascular remodeling and inhibiting the pulmonary artery high pressure rising; therefore, the atorvastatin can be applied to preparation of the drug for treating the pulmonary hypertension.

A mutual prodrug of a corticosteroid and a substituted phenylphosphate (β-agonist derivative) for formulation for delivery by aerosolization to inhibit pulmonary inflammation and bronchoconstriction is described. The mutual prodrug is preferably formulated in a small volume solution (10-500 μL) dissolved in a quarter normal saline having pH between 5.0 and 7.0 for the treatment of respiratory tract inflammation and bronchoconstriction by an aerosol having mass median average diameter predominantly between 1 to 5μ, produced by nebulization or by dry powder inhaler.